<DOC>
	<DOC>NCT02669758</DOC>
	<brief_summary>The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.</brief_summary>
	<brief_title>A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject has completed the 4week treatment period (all visits up to and including end of treatment visit) in the antecedent study ALK3831A305 within 7 days. Agrees to use an acceptable method of contraception for the duration of the study. Additional criteria may apply. Subject is currently taking medications that are contraindicated with olanzapine use. Subject has a positive test for drugs of abuse at study entry. Subject is pregnant, planning to become pregnant, or breastfeeding during the study. Additional criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Safety</keyword>
</DOC>